since I Slide therapy. and talked everyone. Pete, and right about we happening good recognizing on to Thank then, you, the innovation continue progress. gene like Please this X. last turn morning, to to I'd incredible by see neurotherapeutics And call. start now in tremendous our in
recent in neurotherapeutics last Friedreich's of sclerosis. as coverage. approval Alzheimer's ataxia approvals well for amyotrophic neurotherapeutics approvals medicines Medicare front, FDA the lateral just other follows and disease On lecanemab month, including for full received the space, This as FDA
hemophilia the We of to the them. we believe both continues and To fields, recent Voyager to importantly in delivery to therapy. leverage A. neurotherapeutics CNS, gene gene muscular the therapy has first system, sits central uniquely advancements and advance dystrophy gene of with nervous therapies challenging. The and combine the or positioned are therapies of at for into gene intersection Duchenne date, approvals field FDA the proven also
these to companies. parenchyma or generally continue the XXXX. we setbacks the inject various for result and have vasculature to pivoted cerebrospinal recognized spaces the through innovative our in design. been That's penetrate not therapies this back something successful to to other Approaches delivery, fluid we Voyager why intravenous CNS, have enabled in leveraging capsid brain into
review potential. investment Moving to partnerships will briefly pipeline, platform, Slide X, rationale, our I and
to multiple First, capsids the platform. platform generate Voyager novel following delivery. families IV with discovery robust of CNS uses capsid tropism our TRACER
We have presented data to demonstrating multiple species. multiple brain areas the across activity strong transduction within and
dose Society low greater the showed most data relatively Our than brain ASGCT, Therapy, areas VG of or multiple kilogram per for at XEXX at recent in marmosets. the XXXX XX% and Cell American in transduction Conference Gene
our Second, pipeline.
early currently We gene minute. this research Alzheimer's antibody filings, towards ALS. IND today advance a initiative owned in for including to including vectorized are We our program SODX programs and therapy new wholly anti-tau just CNS antibody. advancing four about disease, owned research We'll Alzheimer's and disease through for a have talk targeting late the assets more wholly three anti-Aβ stage announced
patients. partnering total Sangamo around has million number with disease, year agreement than executed Voyager this to revenue alone QX, our opportunities well non-dilutive and/or and with XX. data additional more Voyager for partner partnerships. generate royalty Third, opportunities importantly, of to as generated help we milestone our license $XXX in most provide programs In programs a prion revenue. These to bringing capsids, as to
of neurogenetic therapy gene medicine. potential potential; the specifically into Finally, to approaches from expand other
have across one ASGCT for of the blood attended progress After in now families, macromolecules a good our a receptor receptor also required our who know, for we identified of for of those transport identifying many this we receptor, has the program. which our making barrier, As standing-room-only-talk characteristics BBB. brain you at are ligand capsid of or
We shuttle medicines genetic are the to BBB. the exploring non-viral leverage across receptor potential to the
preliminarily conducting two families additional capsids TRACER receptors of for to have We research validate we and confirmatory discoveries. our identified also these further are
medicine. potential this While increasingly into excited about I'm approaches early, is program reach of to technology other of the expand the here our neurogenetic
Moving to Slide X.
is As robust you a can quite see, advancing pipeline. Voyager
funded in and However, do require investment at we time of partners. four programs They slide the The of doing so blue bottom not a executed Voyager. money depicted are significant efficiently. the by or from are
our programs seven depicted yellow programs Neurocrine. Moving in collaborative the up with the represent slide,
fully orange This in our pipeline. is The these focus will collaborative reimbursed Voyager's programs, I our research. at of the the top wholly owned where depicted for For represent today. six programs slide
Turning to X. Slide
can that three pipeline owned programs disease. Alzheimer's You see wholly now for our includes
lead enabling Our IND this of program anti-tau which advancing antibody, studies our is is initiation towards humanized year.
We expect continue of file the IND to half to XXXX. first an in
research introduced conduct to gene are research we the the program early reduce we In silencing with this tau program This continue delivered which program, combining vectorized a a are Today, our earlier siRNA year. TRACER Alzheimer's early program, brain. we a introducing capsid to vectorized utilizes our this antibody tau anti-Aβ capsid. expression another we franchise. on TRACER in in with Additionally, disease
I call more chosen But to has first, Voyager over turn want owned about three explain the our who Alzheimer's to talk on why Todd this programs will wholly six disease. program to focus momentarily. I will of
with a row represent progress first course These some On the highlights Slide recent across top glance the steps Alzheimer's towards modifying X, of tremendous anti-amyloid antibodies. the of disease.
of there’s tau Alzheimer's on of an milestones disease. of in slide, row role second the body increasing the to data demonstrating Turning this
point of Lilly clinical and bullet. showed to demonstrating data increasing treatment tau as causes of burden. at with which amyloid think of spread that neurodegeneration. lower this what tau cause the benefit trigger amounts There’s in a anti-amyloid tau The reinforced and as greater is a spread that amyloid I patients tipping tau
any evidence already anti-amyloid subtype. efficacy not stage to of anti-amyloid responders, further may non-responders Phase Complete by treatments need treatment based complete data. the anti-amyloid. X and treatment Ultimately, partial clinical responders, see we of than need We to on responders recent better to starting understand and may be
But partial of switching non-responders against is affects for combination responders therapies. done. work to that of targets, much anti-tau and The candidates short, field multiple anti-amyloid be a anti-amyloid appropriate disease And people. monotherapy. anti-tau making this and progress millions for to might In still to be a there's be great is may
to therapy to turn I gene about the our anti-amyloid Now, new over will Todd program. call talk
